ClinicalTrials.gg
Not yet recruitingNCT06344533Updated Apr 3, 2024

Study of JMKX003142 Injection in Chinese Healthy Subjects

A Phase 1 interventional study of JMKX003142 Injection and Placebo in Healthy Adult, sponsored by Jemincare. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Jemincare · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Injection Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Doses in Chinese Healthy Adult Subjects

02

Conditions studied

  • Healthy Adult
03

In context

Lead sponsor

Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects aged 18-45 years (including boundary values).
  2. Able to sign a written form.
  3. Physical examination, clinical laboratory examination value, Virology examination, vital signs and examination are confirmed by the researcher to be normal or abnormal without clinical significance
  4. The subjects have a thorough understanding of the study content, process, and potential adverse effects, and are willing to complete the study according to the requirements of the experimental protocol

Exclusion criteria

Exclusion Criteria:

  1. Had or currently have serious clinical diseases related to circulatory system, respiratory system, digestive system, nervous system, endocrine system, blood lymphatic system, genitourinary system or psychiatry, as well as habitual constipation, gastrointestinal bleeding history, which is judged to be inappropriate for the study by the investigators
  2. Participants in any other clinical study within 3 months prior to the first administration of this study
  3. The investigators believe that the subject has other factors that are not suitable for participating in this experiment
  4. Pregnant or lactating women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    JMKX003142 Injection

    Single and multiple doses of JMKX003142 Injection administered intravenously.

    Drug: JMKX003142 Injection

  • Placebo comparator
    Placebo

    Placebo administered intravenously.

    Drug: Placebo

Interventions

  • JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.

  • DrugPlacebo

    Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.

06

What researchers measure

Primary outcomes

  1. Number of the Adverse Events that are related to the single dose treatment

    single dose safety single dose safety

    Time frame: From Baseline to Day7

  2. Number of the Adverse Events that are related to the multiple dose treatment

    multiple dose safety multiple dose safety

    Time frame: From Baseline to Day12

07

Study locations

1 site
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
    • Haiyan Li · Contact
    • Haiyan Li, MD · Principal investigator
    • Dongyang Liu, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2024; primary completion for Jan 2025, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2024
First posted
Apr 3, 2024
StartEst.
Apr 10, 2024
Primary completionEst.
Jan 31, 2025
CompletionEst.
May 30, 2025
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06344533
Lead sponsor
Jemincare
Collaborators
Zhejiang Hangyu Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Apr 3, 2024
Start date
Apr 10, 2024 (estimated)
Primary completion
Jan 31, 2025 (estimated)
Completion
May 30, 2025 (estimated)
Last update
Apr 3, 2024

Study contacts

Yiming Dong, MD
Contact
dongyiming@jemincare.com
021-58306003
Haiyan Li, MD
Contact
haiyanli1027@hotmail.com
010-82266226

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JMKX003142

Start the discussion